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Background: Gold nanoshells are excellent agents for photothermal ablation cancer therapy 
and are currently under clinical trial for solid tumors. Previous studies showed that passive 
delivery of gold nanoshells through intravenous administration resulted in limited tumor 
accumulation, which represents a major challenge for this therapy. In this report, the impact of 
direct intratumoral administration on the pharmacokinetics and biodistribution of the nanoshells 
was systematically investigated.
Methods: The gold nanoshells were labeled with the radionuclide, copper-64 (64Cu). Intratumoral 
infusion of 64Cu-nanoshells and two controls, ie, 64Cu-DOTA (1,4,7,10-tetraazaciclododecane-
1,4,7,10-tetraacetic acid) and 64Cu-DOTA-PEG (polyethylene glycol), as well as intravenous 
injection of 64Cu-nanoshells were performed in nude rats, each with a head and neck squamous 
cell carcinoma xenograft. The pharmacokinetics was determined by radioactive counting of 
serial blood samples collected from the rats at different time points post-injection. Using 
positron emission tomography/computed tomography imaging, the in vivo distribution of 
64Cu-nanoshells and the controls was monitored at various time points after injection. Organ 
biodistribution in the rats at 46 hours was analyzed by radioactive counting and compared 
between the different groups.
Results: The resulting pharmacokinetic curves indicated a similar trend between the intratumor-
ally injected agents, but a significant difference with the intravenously injected 64Cu-nanoshells. 
Positron emission tomography images and organ biodistribution results on rats after intratumoral 
administration showed higher retention of   64Cu-nanoshells in tumors and less concentration 
in other healthy organs, with a significant difference from the controls. It was also found that, 
compared with intravenous injection, tumor concentrations of 64Cu-nanoshells improved sub-
stantially and were stable at 44 hours post-injection.
Conclusion: There was a higher intratumoral retention of  64Cu-nanoshells and a lower 
concentration in other healthy tissues, suggesting that intratumoral administration is a potentially 
better approach for nanoshell-based photothermal therapy.
Keywords: gold nanoshells, intratumoral administration, positron emission tomography, 
biodistribution
Introduction
One of the most promising recent advances in cancer treatment has been thermal 
ablation, which provides a minimally invasive or noninvasive technique that rapidly 
kills cancer cells by heat. Among the various thermal ablation methods, gold nanoshell-
assisted photothermal ablation, a laser-induced thermal therapy that utilizes the special 
optical properties of gold nanoshells, offers advantages over traditional thermal 
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therapies and has already demonstrated effectiveness in the 
elimination of solid tumors in animal models.1,2 Clinical 
investigation of nanoshells in head and neck cancer patients 
is ongoing. Nanoshells are spherical nanoparticles consisting 
of a dielectric core and a metal shell, where the plasmon 
resonance frequency is determined by the relative size of 
the core and the metal shell layer.3 By adjusting the relative 
core and shell thicknesses, nanoshells can be fabricated to 
absorb or scatter light across the visible and near-infrared 
regions (700–1300 nm) of the electromagnetic spectrum, 
where optical transmission through tissue is optimal. They 
can be manufactured with size ranges (60–400 nm) that can 
accumulate in tumors via the enhanced permeability and 
retention effect, which is attributed to the leaky nature of 
tumor vessels.4 However, our previous research found that 
accumulation of nanoshells in solid tumors via the enhanced 
permeability and retention effect is very limited when they 
are injected intravenously,5–7 which hinders the efficacy of 
subsequent photothermal ablation, and is a major challenge 
for this therapy.
Direct intratumoral injection of anticancer agents has 
been extensively evaluated in the past few decades.8–12 
Studies have suggested that intratumoral injection can 
increase the concentrations of agents at the target site, while 
decreasing their localization to healthy tissues. However, 
intratumoral injection has not been established as an 
alternative route of administration in routine clinical practice. 
This is probably due to the relatively rapid clearance of the 
administered drugs from tumors, high toxicities in tissues 
surrounding the site of application, and availability of other 
more standardized treatment modalities (eg, surgery and 
radiotherapy) to the types of tumors (mostly solid tumors 
and surface tumors) accessible for intratumoral injection.13 
However, these concerns are not necessarily significant 
for some contemporary cancer agents. For example, 
there have been many reports of intratumoral injection 
of different nanocompositions, such as liposomes,14,15 
magnetic cationic liposomes,16 hyaluronan nanoparticle 
formulations,17 N-(2-hydroxypropyl)-methacrylamide 
copolymer,13 cisplatin-loaded polycaprolactone polymers,18 
holmium-loaded poly-L-lactide polymers,19 docetaxel-
loaded polycaprolactone polymers,20 multiwalled carbon 
nanotubes,21 gold-dendrimer composite nanodevices,22 folate-
conjugated shell cross-linked nanoparticles,23 and gum Arabic 
glycoprotein-functionalized gold nanoparticles.24 However, 
intratumoral injection of other newly developed nanoparticles 
has been rarely reported, although it is theoretically a 
good route of administration. For example, mesoporous 
silica nanocomposite systems including gold nanoshells, 
dye-doped silica nanoparticles, and iron-oxide shell silica 
core nanoparticles were only studied by intravenous 
administration.25 Layer-by-layer-assembled materials have 
been developed chiefly for either implantation or injection, 
and the intravenous, intraperitoneal, or subcutaneous injection 
routes provide different biodistribution profiles, while 
targeted delivery using specific targeting molecules have 
also been investigated, but intratumoral administration has 
not been reported.26–28 Quantum dots have been investigated 
extensively by surface conjugation with different targeting 
moieties so that they can be biocompatible and achieve better 
delivery to the target sites; again most of the in vivo studies 
were done intravenously.29 Von Maltzahn et al reported 
x-ray computed tomography (CT) images of gold nanorods 
in animal tumors that were intratumorally injected into mice, 
but they did not systematically compare the biodistribution of 
gold nanorods administered by intratumoral and intravenous 
injection.30 Recently, Huang et al re-examined active and 
passive tumor targeting using gold nanorods, and found 
active molecular targeting of the tumor microenvironment did 
not significantly influence nanoparticle uptake by the tumor, 
suggesting intratumoral injection rather than intravenous 
injection as the preferred route of nanorod administration,31 
although follow-up intratumoral administration studies have 
not been reported.
Here we report for the first time an investigation of the 
feasibility of injecting gold nanoshells directly into solid 
tumors for subsequent near-infrared photothermal therapy. 
Because this therapy has been mainly used for solid tumors as 
well as easily accessible surface tumors, to which intratumoral 
administration is well suited, we chose nude rats with head 
and neck squamous cell carcinoma (HNSCC) xenografts as 
our animal model. To investigate the fate of nanoshells after 
intratumoral administration and compare the outcome with 
that of intravenous administration, in vivo pharmacokinetics 
and biodistribution data are required, and can be obtained by 
labeling gold nanoshells with photon-emitting radionuclides 
and carrying out multiple assessments using noninvasive 
imaging techniques in the same animal across different 
time points. Previously, we have reported a method for 
radiolabeling gold nanoshells with both copper-64 (64Cu) 
and indium-111 (111In) through a bifunctional polyethylene 
glycol (PEG) and 1,4,7,10-tetraazaciclododecane-1,4,7,10-
tetraacetic acid (DOTA), a chelating agent.5–7 Radiolabeling 
a chelating agent with these agents permits determination 
of the biodistribution of radiolabeled nanoshells in live rats 
bearing HNSCC xenografts by noninvasive positron emission 
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tomography (PET) and single-photon emission computed 
tomography (SPECT) imaging.5–7
The studies reported here were conducted by labeling gold 
nanoshells with radionuclide 64Cu, using small-animal PET/
CT imaging of rats with HNSCC xenografts at various time 
points after administration, obtaining pharmacokinetic data 
from the measurement of radioactivity in blood samples, and 
post-sacrifice tissue counting to determine the distribution of 
64Cu-nanoshells. The retention and intratumoral distribution 
of 64Cu-nanoshells were assessed by both imaging and tissue 
biodistribution studies, and the results were compared 
between animals that were intratumorally and intravenously 
injected with  64Cu-nanoshells to determine the potential 
benefit of intratumoral injection for gold nanoshell-assisted 
photothermal ablation cancer therapy. In addition, the 
in vivo stability of the 64Cu-nanoshell labeling method was 
indirectly assessed by comparing the tissue biodistribution 
patterns of 64Cu-nanoshells with those of two separate 64Cu 
labeling controls, ie,  64Cu-DOTA and  64Cu-DOTA-PEG. 
Intratumoral administration was demonstrated to improve 
tumor accumulation of the gold nanoshells significantly up 
to 44 hours, with excellent stability and lower concentrations 
in healthy tissue. Our study indicates that intratumoral 
administration of gold nanoshells could be an ideal method 
for treating larger solid tumors directly with thermal therapy 
while minimizing thermal damage to surrounding normal 
tissues.
Materials and methods
Radiolabeling of nanoshells
The gold nanoshells were synthesized as previously 
described.32 Gold nanoshell formation was assessed using 
an ultraviolet-visible spectrophotometer (U-0080D, Hitachi, 
Schaumburg, IL) and Zetasizer (Nano-ZS, Malvern, 
Westborough, MA). Nanoshells manufactured in this manner 
have an 8–10 nm gold shell around a 110–120 nm silica 
sphere. The radiolabeling process for the gold nanoshells 
has been described in our previous publications.5–7 As 
Figure 1A shows, a bifunctional chelating agent DOTA-NH2 
(S-2-(4-aminobenzyl)-1, 4, 7, 10-tetraazacyclododecane 
tetraacetic acid, Macrocyclics, Dallas, TX) was conjugated 
to bifunctional OPSS-PEG-NHS (opyridyldisulfide-PEG 
2000-N-hydroxysuccinimide ester, Nektar, Huntsville, AL). 
DOTA-NH2 and OPSS-PEG-NHS were mixed in a 1:1 molar 
ratio and the mixture was incubated overnight at room 
temperature. The resulting OPSS-PEG-DOTA was then added 
to a nanoshell solution (in 10 mM phosphate buffer, pH 7) at 
a 10,000:1 molar ratio, followed by overnight incubation at 
room temperature on a shaker, allowing the OPSS group to 
conjugate with the gold surface of the particles. The mixture 
was centrifuged and the supernatant with unconjugated 
OPSS-PEG-DOTA was removed. The pellets of DOTA-gold 
nanoshells were resuspended in phosphate buffer and checked 
with the spectrophotometer and Zetasizer to determine the 
gold nanoshell concentration and size for further conjugation. 
All the radioactive research was performed at the Department 
of Radiology, University of Texas Health Science Center at 
San Antonio. 64CuCl2 (Washington University, St Louis, MO) 
was diluted in 30 mM ammonium citrate buffer (pH 6.5). 
Next, 213 mBq (5.76 mCi) of 64Cu was added to 450 µL of 
the DOTA-gold nanoshell solution (about 0.8 nM) followed 
by the addition of blocking agent PEG5k-SH (Nektar) in a 
300,000:1 molar ratio and incubation at room temperature on 
a shaker for one hour. The mixtures were then centrifuged to 
remove the unconjugated 64CuCl2 and PEG5k-SH. The 64Cu 
activity of the supernatant and pellet were measured in a dose 
calibrator (Atomlab 100, Biodex, Shirley, NY). The labeling 
efficiency of the 64Cu nanoshells was calculated as [activity 
in pellet/(activity in supernatant + activity in pellet)] × 100, 
which was 81.3%.
The control samples were 64Cu-DOTA and 64Cu-DOTA-PEG. 
64Cu-DOTA was prepared by mixing 74 mBq (2.0 mCi) of 
64CuCl2 with 200 µL of 0.20 mM DOTA solution (pH 6.5) and 
incubating at 37°C for 90 minutes. The 64Cu-DOTA-PEG was 
prepared by mixing 74 mBq (2.0 mCi) of 64CuCl2 with 200 µL 
of 0.20 mM DOTA-PEG solution (pH 6.5) and incubating 
at 37°C for 90 minutes. Formation of 64Cu complexes were 
verified by radiothin layer chromatography using a mobile 
phase consisting of 50:50 MeOH/10% ammonium acetate 
on silica plates.
Animal model, intratumoral infusion,  
and image acquisition
A human HNSCC xenograft model in nude rats was 
established via subcutaneous inoculation of a HNSCC cell 
line (SCC-4), as reported previously.33 Animal experiments 
with radioactive agents were performed at the University of 
Texas Health Science Center at San Antonio according to 
the National Institutes of Health animal use guidelines and 
Institutional Animal Care and Use Committee approval.
All animals were treated 14 days after tumor cell 
inoculation. On that day, the average weight of the rats 
was 199.3 ± 17.2 g and the average tumor volume was 
1.84 ± 0.61 cm3. During each animal handling procedure, 
the animals were anesthetized by inhalation of 1%–3% 
isoflurane (Vedco, Saint Joseph, MO) in 100% oxygen with 
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use of a veterinary inhalant anesthesia machine (Bickford, 
Wales Center, NY). Three groups of rats were intratumorally 
treated, with two controls, ie, 64Cu-DOTA (n = 3, group 1) 
and 64Cu-DOTA-PEG (n = 3, group 2) as well as 64Cu-NS 
(n = 4, group 3), respectively. For all the above groups, the 
tumors were infused with an infusion pump (KD Scientific, 
Holliston, MA) to deliver the assigned therapy volume and 
radioactivity. The rate of infusion was 0.5 mL/minute. The 
radioactivity of the infusion solutions was 577, 528, and 
600 µCi/mL for groups 1, 2, and 3, respectively. A 23-gauge 
needle attached to an infusion pump by polyethylene tubing 
was inserted into the tumor as guided by direct visual place-
ment and palpation. The total infusion volume for each rat 
tumor was 30% of the tumor volume from caliper measure-
ments determined on the day of the study. To achieve better 
tumor coverage, each animal received a series of three per-
cutaneous injections (10% of total tumor volume with each 
injection) with a 15-minute gap between each consecutive 
injection. The needle placements for each injection were 
equally spaced along the largest central section area of the 
tumor, with each needle tip at approximately one third depth 
in the tumor along the needle insertion direction.
A separate control group of nude rats bearing HNSCC 
tumors (n = 4, group 4) was intravenously injected with 
64Cu-nanoshells (0.5 mL of 460–490 µCi of 64Cu activity) into 
the tail vein. The rat tail was large enough to insert a needle 
in the contralateral vein or in a place well above the injection 
site for collecting the subsequent blood samples.
One rat from group 1, one rat from group 2, all four rats 
from group 3, and all four rats from group 4 were selected 
for PET/CT imaging at hours 1, 4, 20, and 44 post-injection 
using FLEX X-PET/CT/SPECT (Gamma Medica-Ideas Inc, 
Northridge, CA) followed by CT image acquisition (80 kVp, 
0.25 mA, 256 projections).
Pharmacokinetic and biodistribution 
studies
Blood samples (40 µL) were collected from the tail veins of 
the anesthetized nude rats from groups 1 to 4 at 5 minutes 
and hours 1, 4, 20, and 42 post-injection. 64Cu radioactivity 
in the blood samples were measured by a gamma-counter 
(Wallac 1480, Perkin Elmer Life Sciences, Boston, MA). 
The data are presented as average ± standard deviation 
from each group. The SigmaPlot 10.0 (Systat Software Inc, 
San Jose, CA) was used to obtain the curve fitting for the 
pharmacokinetic data.
After completion of the last imaging session and blood 
collection, the rats were sacrificed at 46 hours post-injection 
by cervical dislocation under deep isoflurane anesthesia. The 
organs of interest were removed and wet-weighed. Radioac-
tivity in the tissues was measured using a gamma counter. 
The radioactivity of the tissue samples was normalized 
against a known aliquot of the injectate. The percent injected 
dose per gram of tissue (%ID/g) values were calculated using 
the following equation:
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Figure 1 (A) Radiolabeling scheme of gold nanoshells with 64Cu through bifunctional OPSS-PEG-NHS and DOTA-NH2. (B) Ultraviolet-visible spectra of gold nanoshells 
before and after conjugation with OPSS-PEG-DOTA. 
Abbreviations: PEG, polyethylene glycol; DOTA, 1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid; NS, gold nanoshells; NHS, hydroxysuccinimide ester; OPSS, 
opyridyldisulfide.
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The percent injected dose per organ (%ID/organ) values 
were calculated using the following equation:
%ID/organ
(CPM in sample Background)   (Correction factor)
=
-×      100
  (CPM in standard)   
(Injection volume)
(Standard vo
×
×
l lume)
Total activity in bone, muscle, and skin was calculated 
assuming 10%, 40%, and 13% of the rat body weight, 
respectively.34,35
Statistical analysis
All values are expressed as average ± standard deviation. 
One-way analysis of variance and post hoc multiple 
  comparison (Bonferroni’s t-test) on the pharmacokinetic 
and biodistribution data (%ID/g and %ID/organ) were 
performed using Systat 12 (Systat Software Inc, San Jose, 
CA). P values ,0.05 were considered to be statistically 
significant.
Results
Radiolabeling of nanoshells
Nanoshells used in this study were manufactured to be 
comprised of a silica core (about 120 nm in diameter) and 
a gold shell (8–10 nm) to absorb light at the near-infrared 
region. The ultraviolet-visible spectrum showed the nano-
shell peak at about 760 nm (Figure 1B). Zetasizer mea-
surements showed the nanoshell size was around 140 nm 
in diameter and zeta potential was around -50 mV. A 
conjugation procedure developed previously7 was applied 
to label the nanoshells with 64Cu (elimination half-life 
12.7 hours), using bifunctional OPSS-PEG-NHS and the 
bifunctional chelating agent, DOTA-NH2 (Figure 1A). First, 
OPSS-PEG-NHS and DOTA-NH2 were mixed, and the 
NHS ester reacted with the amine group to form an amide 
bond. The mixture was then added to a nanoshell solution, 
allowing the OPSS group to attach to the gold surface of the 
particles to obtain gold nanoshell-PEG-DOTA. Ultraviolet-
visible spectra show that this intermediate had a peak at 
765 nm, slightly shifted to a higher wavelength (Figure 1B), 
which normally indicates successful conjugation. Gold 
nanoshell-PEG-DOTA were then coupled with 64Cu through 
DOTA. Finally, the longer PEG5k-SH was added to block 
the remaining empty areas on the gold surface to provide 
better PEG coverage. Zetasizer measurements showed 
that, after surface modification, the gold nanoshell size 
increased to about 170 nm in diameter and zeta potential 
was around -5 mV .
Pharmacokinetics
First, the impact of intratumoral injection on the circulation 
kinetics of 64Cu-nanoshells and its two controls, 64Cu-DOTA 
and 64Cu-DOTA-PEG, were investigated in nude rats with 
human HNSCC xenografts. Blood samples were collected 
at 5 minutes, and at hours 1, 4, 20, and 42 post-injection for 
radioactive counting. The simulated exponential decay cir-
culation curves (three-parameter exponential decay model) 
were obtained for 64Cu-DOTA, 64Cu-DOTA-PEG2 K, and 
64Cu-nanoshells based on the average %ID in the blood 
samples from rats in each group (three rats per group for 
the two controls and four rats per group for 64Cu-nanoshells) 
at the same time points (Figure 2A). In general, these three 
curves have very similar decay, with a higher percentage of 
64Cu-nanoshells entering the systemic circulation at 5 min-
utes post-injection, but there were only small portions of 
all of these materials left in the blood after one hour. The 
pharmacokinetic behaviors of these materials are quite dif-
ferent than when intravenously administered, as we have 
reported previously.7
Next, the circulation kinetics of intratumorally 
administered and intravenously administered 64Cu-nanoshells 
were compared. As Figure 2B shows, up to 42 hours post-
injection, the blood concentrations of intratumorally applied 
64Cu-nanoshells were significantly lower than those of 
intravenously administered  64Cu nanoshells. At one hour 
and 42 hours post-injection, for example, 22.5% ± 13.6% 
and 2.3% ± 0.2% ID were found in blood for intratumoral 
injection, compared with 42.8% ± 6.9% (P , 0.0001) and 
4.0% ± 1.0% ID (P = 0.014, P , 0.05) for intravenous 
injection. This indicates that a large portion of intratumorally 
injected gold nanoshells are retained in the tumor and only 
a small percentage entered the systemic circulation. For 
intravenous injection, gold nanoshells are required to have 
reasonable stability in the circulation and to avoid recognition 
by the reticuloendothelial system so that a higher percentage of 
nanoshells can enter the targeted tumor site. The intravenously 
injected  64Cu-nanoshells had an average blood clearance 
half-life of 12.76 hours in the tumor-bearing rats, which is 
similar to other intravenously injected gold nanoparticles with 
smaller size.30,36 The different administration routes leading to 
the different pharmacokinetic behaviors of 64Cu-nanoshells 
are shown here.
PET imaging
Using PET/CT imaging, we monitored the in vivo 
distribution at various time points after intratumoral 
administration of 64Cu-nanoshells and the two controls as 
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well as intravenous injection of  64Cu-nanoshells in nude 
rats with HNSCC xenografts. Figure 3 shows the PET 
coronal images of three rats at hours 1, 4, 20 and 44 after 
intratumoral injection of 64Cu-DOTA, 64Cu-DOTA-PEG, and 
64Cu-nanoshells, as well as the corresponding CT images 
denoting the location of the tumor in each rat. As we can 
see, the amount of the two control substances retained in the 
tumor decreased slowly over the first 20 hours but became 
very weak at 44 hours post-injection. Correspondingly, there 
was some accumulation in the liver and spleen at one hour 
which declined over time, suggesting that the controls cleared 
rapidly from the body. This observation agrees with the 
pharmacokinetic curves shown in Figure 2A. In contrast, 
the 64Cu-nanoshells maintained high concentrations in the 
tumor up to 44 hours; uptake to the liver and spleen was 
consistent in the first 20 hours, and became almost invisible 
at 44 hours post-injection, which suggests slower clearance 
than for the two controls, but stable and high tumor retention 
of gold nanoshells at the end time point. These results also 
confirm that the radioisotope distribution truly reflected the 
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Figure 2 Pharmacokinetics, expressed as a percentage of the injected dose (%ID) in blood, of (A) 64Cu-DOTA, 64Cu-DOTA-PEG, and 64Cu-NS at 5 minutes, and at hours 1, 
4, 20, and 42 after intratumoral injection, and (B) 64Cu-nanoshells administered by intratumoral versus intravenous injection. 
Notes: The data points are the average values of three rats for 64Cu-DOTA and 64Cu-DOTA-PEG and the average values of four animals for 64Cu-nanoshells (average ± standard 
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Abbreviations: PEG, polyethylene glycol; DOTA, 1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid; NS, gold nanoshells; IT, intratumoral; IV, intravenous.
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gold nanoshell distribution because it was quite different 
from the two other controls, which agrees with our previous 
report.7
PET images showing the tumor localization and organ 
distribution of intratumorally and intravenously administered 
gold nanoshells were compared. As displayed in Figure 4, 
64Cu-nanoshell tumor accumulation at one hour after intra-
venous injection was insignificant, but increased over time. 
The slowly increased tumor uptake was due to slow removal 
of 64Cu-nanoshells from the blood pool, as denoted by heart 
activity on the one-hour image and the pharmacokinetic data 
depicted in Figure 2B. However, the amount of particles in 
tumor was much lower compared with the rat with intratu-
moral injection at any time point. Correspondingly, signals on 
the liver and spleen were much higher for the intravenously 
injected rat than the intratumorally injected one at all time 
points, especially at 44 hours post-injection. These results 
agree with each other and indicate significant uptake of intra-
venously injected gold nanoshells by the reticuloendothelial 
system, suggesting that intratumoral injection was a better 
administration route to provide a high concentration of gold 
nanoshells at tumor site and low accumulation in the organs 
of the reticuloendothelial system.
Biodistribution
All the rats were sacrificed at 46 hours post-injection, and 
major organs were collected. The amount of 64Cu-DOTA, 
64Cu-DOTA-PEG, and 64Cu-nanoshells in the   tissue samples 
Figure 3 Coronal PET images of three HNSCC xenograft-bearing nude rats acquired at various time points after intratumoral injection of 64Cu-DOTA, 64Cu-DOTA-PEG, 
and 64Cu-NS, respectively. 
Notes: Surface-rendered CT images depicting tumor location are also shown. Color intensity scale is denoted as red . yellow . green . blue. 
Abbreviations: L, liver; S, spleen; T, tumor; PEG, polyethylene glycol; DOTA, 1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid; NS, gold nanoshells; PET, positron 
emission tomography; CT, computed tomography; HNSCC, head and neck squamous cell carcinoma.
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was quantified by gamma well counter. The percentages 
of injected dose (all given by intratumoral injection) per 
gram of tissue and per organ were calculated and shown 
in Table 1. Statistical analysis was performed to compare 
the differences in tissue uptake between the two controls 
and the 64Cu-nanoshells. As we can see, accumulation of 
the 64Cu-nanoshells in the tumor, spleen, liver, and urine 
(0–20 hours) was significantly different from that of the two 
controls (P , 0.05). For the 64Cu-nanoshells, the highest 
%ID was located in the tumor (31.12% ID/organ) followed 
by the liver, a reticuloendothelial system organ (13.91% ID/
organ). It seems that after intratumoral administration, a 
small percentage of the 64Cu-nanoshells was rapidly taken 
up by the spleen and liver, and then slowly cleared through 
the intestine, as evident from the 7.27% ID found in feces 
at 46 hours post-injection. In contrast,  64Cu-DOTA and 
64Cu-DOTA-PEG were rapidly taken up by the liver and 
kidneys, and then quickly eliminated as feces and urine. 
Urine samples collected at 0–20 hours post-injection 
showed much higher radioactivity in rats injected with 
64Cu-DOTA and 64Cu-DOTA-PEG than in rats injected with 
64Cu-nanoshells (30.63% ID per organ and 18.35% ID per 
organ versus 0.98% ID per organ). These results match the 
PET imaging observations as discussed above, and also fol-
low a trend similar to that of the data for intravenous injec-
tion of 64Cu-DOTA, 64Cu-DOTA-PEG, and 64Cu-nanoshells, 
which we have reported previously.7 They demonstrate 
that elimination of the two controls happened at an early 
stage (before 20 hours post-injection), and confirm that 
the radioisotope was not cleaved from the gold nanoshells 
and that the biodistribution data for the  64Cu-nanoshells 
truly reflected their location. They also demonstrate that 
the elimination patterns for the controls with intratumoral 
injection and intravenous injection were similar.7
We also compared the distribution of  64Cu-nanoshells 
at the tumor site and other tissues of animals treated with 
intratumoral and intravenous injection. Figure 4 shows that, 
with intravenous injection, a higher %ID per gram of tissue 
was detected in the spleen, liver, and feces, followed by the 
kidney and tumor; the higher %ID per organ was found 
in, eg, the liver, feces, and muscle, whereas tumor uptake 
was very limited. However, with intratumoral injection, the 
highest %ID per gram of tissue was observed in the spleen,   
followed by tumor; the highest %ID per organ was found 
Figure 4 Positron emission tomographic images of two head and neck squamous cell carcinoma xenograft-bearing nude rats acquired at various time points after intratumoral 
injection and intravenous injection of 64Cu-nanoshells. For intratumoral injection, gold nanoshell accumulation in tumor remained consistently high during the 44 hours post-
injection period; the accumulation in liver and spleen could be observed in the first 20 hours, but became much less at 44 hours. For intravenous injection, gold nanoshell 
accumulation in tumor was much less compared with intratumoral injection throughout the 44 hours; the highest amount of gold nanoshells were found in the spleen and 
liver. 
Notes: Surface-rendered CT images depicting tumor location are also shown. Color intensity scale is denoted as red . yellow . green . blue. 
Abbreviations: H, heart; L, liver; S, spleen; T, tumor; CT, computed tomography; IT, intratumoral; IV, intravenous.
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Table 1 Biodistribution data of 64Cu-DOTA, 64Cu-DOTA-PEG, and 64Cu-NS in HNSCC xenograft-bearing nude rats (n = 3, n = 3, and 
n = 4) at 46 hours after intratumoral administration
Organ 64Cu-DOTA 64Cu-DOTA-PEG 64Cu-NS
%ID/g %ID/organ %ID/g %ID/organ %ID/g %ID/organ
Tumor 1.64 ± 1.02   6.90 ± 3.01 1.34 ± 0.43   5.49 ± 1.22   6.28 ± 1.68* 31.12 ± 6.63*
Spleen 0.10 ± 0.01   0.05 ± 0.00 0.17 ± 0.02   0.08 ± 0.01 11.63 ± 9.69   3.50 ± 2.16*
Liver 0.26 ± 0.02   2.67 ± 0.27 0.52 ± 0.10   4.33 ± 0.51   1.34 ± 0.29* 13.91 ± 4.72*
Lung 0.09 ± 0.01   0.09 ± 0.01 0.14 ± 0.03   0.13 ± 0.04   0.17 ± 0.04   0.17 ± 0.06
Kidney 0.39 ± 0.02   0.71 ± 0.10 0.59 ± 0.07   0.97 ± 0.08   0.53 ± 0.13   0.79 ± 0.18
Blood 0.09 ± 0.01   0.98 ± 0.05 0.13 ± 0.02   1.31 ± 0.12   0.16 ± 0.03   1.77 ± 0.35
Skin 0.08 ± 0.01   2.00 ± 0.02 0.13 ± 0.03   3.09 ± 0.57   0.11 ± 0.03   3.01 ± 0.77
Muscle 0.02 ± 0.00   1.99 ± 0.15 0.04 ± 0.01   3.21 ± 0.33   0.04 ± 0.01   3.67 ± 0.86
Bone 0.06 ± 0.01   1.14 ± 0.12 0.08 ± 0.01   1.57 ± 0.20   0.12 ± 0.05   2.40 ± 0.87
Heart 0.10 ± 0.01   0.07 ± 0.00 0.15 ± 0.01   0.09 ± 0.01   0.18 ± 0.05   0.11 ± 0.03
Stomach 0.07 ± 0.02   0.23 ± 0.13 0.13 ± 0.02   0.35 ± 0.27   0.05 ± 0.02   0.26 ± 0.09
Intestine 0.11 ± 0.03   1.31 ± 0.21 0.25 ± 0.07   2.44 ± 0.63   0.21 ± 0.03   2.01 ± 0.45
Cecum 0.14 ± 0.04   0.75 ± 0.34 0.31 ± 0.07   1.60 ± 0.62   0.23 ± 0.05   1.44 ± 0.53
Bladder 0.04 ± 0.02   0.02 ± 0.01 0.09 ± 0.02   0.06 ± 0.02   0.10 ± 0.04   0.06 ± 0.06
Testis 0.08 ± 0.01   0.21 ± 0.04 0.13 ± 0.02   0.29 ± 0.04   0.13 ± 0.03   0.27 ± 0.06
Brain 0.01 ± 0.00   0.02 ± 0.00 0.02 ± 0.00   0.03 ± 0.00   0.02 ± 0.00   0.03 ± 0.01
Urine 0–20 hours 4.34 ± 1.82 30.63 ± 1.78 5.08 ± 3.22 18.35 ± 5.89   0.15 ± 0.11*   0.98 ± 0.66*
Urine 20–42 hours 0.16 ± 0.11   0.63 ± 0.15 0.32 ± 0.22   0.97 ± 0.40   0.16 ± 0.11   0.72 ± 0.49
Feces 1.71 ± 0.42 10.40 ± 2.38 2.85 ± 1.41 18.17 ± 6.80   1.04 ± 0.43   7.27 ± 1.17
Notes: Data are presented as the average ± standard deviation of 3–4 animals per experimental group as percentage injected dose per gram of tissue (%ID/g) and percentage 
injected dose per organ (%ID/organ). *P , 0.05. 
Abbreviations: NS, nanoshells; DOTA, 1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid; PEG, polyethylene glycol; HNSCC, head and neck squamous cell carcinoma.
in tumor, followed by the liver. These results show that, 
compared with intravenous injection, intratumoral injection 
significantly increased the total amount of gold nanoshells in 
the tumor, as well as the amount of gold nanoshells retained 
in the tumor even at 46 hours post-injection (0.77% ID/g of 
tissue versus 6.28% ID/g of tissue, 0.97% ID/organ versus 
31.12% ID/organ, P , 0.001 for both). In addition, intratu-
moral injection also decreased the amount of gold nanoshells 
in healthy tissue, and the differences were significant for most 
tissues (Figure 5, P , 0.05). These findings suggest that intra-
tumoral injection is a better route of nanoparticle administra-
tion that significantly improves nanoparticle accumulation 
at the tumor site and therefore can potentially enhance the 
efficacy of subsequent photothermal ablation therapy.
Discussion
Several significant barriers exist in solid tumors, such as 
a stiff extracellular matrix and elevated interstitial fluid 
pressure,15,37 which greatly impede penetration and distri-
bution of therapeutics throughout the tumor mass. Direct 
intratumoral drug administration can not only bypass the 
major obstacles to systemic delivery, but can also take 
advantage of those barriers to prevent rapid drug clearance 
and promote local retention of therapeutic agents. Therefore, 
this approach has been evaluated relatively extensively for 
improving the therapeutic effectiveness of many anticancer 
agents. Moreover, the feasibility of directly injecting tumors 
has been greatly enhanced recently by advances in imaging 
technology, which permit the use of image-guided interven-
tion systems. These image-guided systems make it possible 
to introduce therapeutic agents into areas once believed to be 
inaccessible without unacceptable risks. However, system-
atic studies on intratumoral injection of metal nanoparticles 
suitable for photothermal ablation have rarely been reported, 
according to our knowledge.
In recent years, nanoparticles have been broadly explored 
as promising therapeutic and imaging agents. The emergence 
of noble metal nanostructures with unique photophysical 
properties has significantly contributed to the development of 
cancer photothermal therapy. Up to now, gold nanospheres, 
gold nanorods, gold nanoshells, gold nanocages, and carbon 
nanotubes have demonstrated photothermal effects due to 
their strongly enhanced absorption in the visible and near-
infrared regions.38 The focus has been mainly on solid gold 
nanospheres (under 100 nm in diameter) coupled with visible 
lasers and gold nanorods (under 100 nm in diameter), and 
gold nanoshells (100–200 nm in diameter) coupled with near-
infrared lasers.38 The absorption spectra of solid nanospheres, 
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nanorods, and nanoshells are sensitive to the size, length/
width ratio, and core/shell ratio, respectively. On the other 
hand, an ideal nanoparticle size for tumor accumulation via 
the enhanced permeability and retention effect is generally 
considered to be in the range of 10–100 nm, with the upper 
limit not well defined.39 Larger particles (220 nm and above) 
are generally cleared faster from the blood by the liver 
(Kupffer cells). Zhang et al reported that 111In-labeled PEG 
5000-thioctic acid-coated gold nanospheres with a diameter 
of 20, 40, and 80 nm had average blood clearance half-lives in 
mice of 22.5 hours, 10.1 hours, and 15.8 hours,   respectively.36 
Von Maltzahn et al reported that their PEG 5000-gold 
nanorods (approximately 13 × 47 nm) had a 17-hour blood 
circulation half-life in mice.30 Our gold nanoshells (with a 
PEG coating) had an average blood clearance half life of 
12.76 hours in tumor-bearing rats,40 which is similar to gold 
nanopheres and gold nanorods of smaller sizes. Therefore, 
their accumulation in tumor tissue should also be similar.
Among the three nanostructures, gold nanoshells have 
demonstrated effectiveness in photothermal ablation of solid 
tumors in animal models,1,2 and are currently under clinical 
trial for head and neck cancer with an approved investigational 
device exemption. In connection with the investigational 
device exemption filing, the Good Laboratory Practices 
preclinical and laboratory studies did not find any systemic 
toxicity associated with infusion of the particles into the 
bloodstream. Based on this evidence, it can be concluded that 
gold nanoshells are biocompatible and nontoxic. Previously, 
we have reported the pharmacokinetics and biodistribution 
of radiolabeled gold nanoshells and their two controls that 
were intravenously injected into nude rats with HNSCC 
tumor xenografts. We found that the accumulation of gold 
nanoshells in tumor tissue through enhanced permeability 
and retention effect was very limited and the majority of the 
gold nanoshells were recognized by the reticuloendothelial 
system and cleared rapidly from the liver and spleen.6,7 
Targeted delivery using targeting moieties such as antibodies, 
peptides, and small molecules has been extensively studied 
in order to improve nanoparticle concentration at the tumor 
site.37,41–44 We have performed targeted delivery of gold 
nanoshells and with RGD peptides specific for integrin 
binding.5 However, accumulation of gold nanoshells only 
increased slightly at 20 hours after intravenous injection 
and no obvious difference was observed at 44 hours, which 
was much less than we anticipated. In addition, Huang et al 
re-examined active and passive tumor targeting using gold 
nanorods and they also found active molecular targeting of the 
tumor microenvironment did not significantly influence tumor 
nanoparticle uptake.31 Therefore, an alternative administration 
method, intratumoral injection, was investigated in order to 
increase tumor accumulation of gold nanoshells while 
decreasing their amount in healthy tissue.
Solid tumors are dense tissues with relatively little 
interstitial space. The number of injections, volume, and even 
rate of injection are all factors that contribute to the initial 
gold nanoshell distribution when given intratumorally. In 
our studies, we applied techniques that had been evaluated 
previously for intratumoral delivery of other   nanoparticles14 
to ensure good tumor coverage. Each rat received a series 
of three percutaneous injections (10% of total tumor 
  volume with each injection) slowly (0.5 mL/minute) with 
a 15-minute gap between each consecutive injection. The 
needle placements for each injection were equally spaced 
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Figure 5 Quantification of the biodistribution of the tumors and organs of head 
and  neck  squamous  cell  carcinoma  xenograft-bearing  nude  rats  administered 
64Cu-nanoshells  by  intratumoral  injection  and  intravenous  injection  at  46  hours 
post-injection. Values represent the average ± standard deviation of four animals 
per experimental group. (A) percentage injected dose per gram of tissue (%ID/gram 
of tissue), and (B) percentage injected dose per organ (%ID/organ). 
Note: *P , 0.05 for intratumoral versus intravenous injection. 
Abbreviations: IT, intratumoral; IV, intravenous.
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along the largest central section area of the tumor, with each 
needle tip at approximately one-third depth in the tumor along 
the needle insertion direction. In addition, dense extracellular 
matrix and the close proximity of cells to one another may be 
considered amongst the most prominent physical barriers that 
limit the movement of the relatively large particles, therefore 
the nanoshell spread within solid tumor may be limited and 
may rarely extend significantly beyond the site of injection.45 
One of the practical challenges in using an intratumoral injec-
tion to perform photothermal cancer therapy is to ensure that 
the injected nanoparticles evenly distribute throughout the 
whole tumor so that all of the cancerous cells can be killed 
by heat generated from the adjacent particles. Use of high-
resolution imaging techniques, such as PET and SPECT, 
can provide detailed intratumoral distribution information 
using a radiolabeled agent. In addition, noninvasive imaging 
techniques may also be important tools for the planning of 
proposed intratumoral injection procedures and for monitor-
ing thermal ablation laser treatment. Our studies in HNSCC 
tumors showed that 64Cu-nanoshells had broad intratumoral 
diffusion, which would clearly be beneficial in providing 
uniformly dispersed gold nanoshells throughout the tumor.
The same strategy can also be applied to other popular 
photothermal agents, such as gold nanorods. Dickerson et al 
reported plasmonic photothermal treatment of deep tissue 
malignancies using gold nanorods that were intratumorally 
and intravenously injected into nu/nu mice. They observed 
a 2.18-fold higher concentration of nanorods at the tumor 
sites for the intratumorally injected mice at 2 minutes and a 
dramatic size decrease in squamous cell carcinoma xenografts 
for intratumoral (P , 0.0001) and intravenous (P , 0.0008) 
administration in the treated mice.46 Further photothermal 
treatment will be undertaken in animals that are intratumor-
ally infused with gold nanoshells for comparison of the thera-
peutic effectiveness with traditional intravenous injection. 
A better assessment of intratumoral administration should 
provide future guidance on current cancer therapy.
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